Metabolic and bariatric surgery and obesity pharmacotherapy for cancer prevention: current status and future possibilities.
Mary C PlaydonSheetal HardikarPrasoona KarraRachel HooblerAnna R IbeleKatherine Loree CookAmanika KumarJoseph E IppolitoJustin C BrownPublished in: Journal of the National Cancer Institute. Monographs (2023)
Obesity is a chronic, relapsing, progressive disease of excess adiposity that increases the risk of developing at least 13 types of cancer. This report provides a concise review of the current state of the science regarding metabolic and bariatric surgery and obesity pharmacotherapy related to cancer risk. Meta-analyses of cohort studies report that metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care. Less is known regarding the cancer-preventive effects of obesity pharmacotherapy. The recent approval and promising pipeline of obesity drugs will provide the opportunity to understand the potential for obesity therapy to emerge as an evidence-based cancer prevention strategy. There are myriad research opportunities to advance our understanding of how metabolic and bariatric surgery and obesity pharmacotherapy may be used for cancer prevention.
Keyphrases
- weight loss
- bariatric surgery
- insulin resistance
- metabolic syndrome
- papillary thyroid
- type diabetes
- weight gain
- squamous cell
- high fat diet induced
- multiple sclerosis
- healthcare
- stem cells
- obese patients
- public health
- body mass index
- palliative care
- risk assessment
- young adults
- randomized controlled trial
- mesenchymal stem cells
- childhood cancer
- squamous cell carcinoma
- physical activity
- smoking cessation
- human health
- lymph node metastasis
- climate change
- cell therapy
- quality improvement